Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjorn T. Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J. W. M. Janssen, Gunnar Juliusson, Johan Maertens, Markus G. Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter J. M. Valk, Bob Löwenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)


Not available.

Original languageEnglish
Pages (from-to)2794-2798
Number of pages5
Issue number10
Early online date6 Apr 2023
Publication statusPublished - 1 Oct 2023

Cite this